| Name | Title | Contact Details |
|---|
Buy Sod/ SodStar Offers You the Most Solutions with 15+ Sensational Turf Varieties! With our widespread network of sod farms, covering thousands of acres, across NC, SC, TN, GA and VA, and a range of hardiness zones and soil types, Buy Sod grows more turfgrass varieties than any other sod grower in the Carolinas or Virginia. Our all-encompassing roster includes traditional cultivars for turf managers wishing to stick to the tried-and-true, as well as newer next-generation grasses, for those seeking improved performance and aesthetic characteristics. No matter what type of site you manage — golf course, sports field, lawn/landscape, commercial property, park, cemetery or roadside right-of-way — we have your best turfgrass solution. Buy Sods branded, high-performance varieties have been thoroughly tested in research trials, with proven qualities that deliver dependable results. And all of our cultivars are grown under rigorous certification protocols, ensuring the genetic purity and integrity of whichever turfgrass you select. Equally important, our advanced routing system fast-tracks your order for rapid delivery even on short notice. Upon delivery confirmation and routing, we email to you a delivery notification with the expected arrival time and a link to a GPS system where you can track exactly where your sod is in route. Nothing is more important to us than not only fulfilling your needs but also exceeding your expectations. Thats why Buy Sod is truly the Professionals Source for Superior Selections and World-Class Service.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.